AI Article Synopsis
- - Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) is a rare condition that involves the growth of skin and gastrointestinal (GI) lesions showing features of both lymphatic and vascular origins.
- - The disorder includes thrombocytopenia, which is a decrease in platelets, believed to result from their destruction within the lesions.
- - A case report highlights the effective use of bevacizumab, an antibody targeting vascular endothelial growth factor, in treating this life-threatening condition associated with severe GI bleeding.
Article Abstract
Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) is a rare disorder characterized by a proliferation of cutaneous and gastrointestinal (GI) lesions that have characteristics of both lymphatic and vascular lesions. Thrombocytopenia is associated with this syndrome and is thought to represent platelet destruction within the lesions. The natural history is one of multiple, life-threatening episodes of GI bleeding. We report the successful use of bevacizumab in this disease, an antibody to the vascular endothelial growth factor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.21860 | DOI Listing |
Publication Analysis
Top Keywords
multifocal lymphangioendotheliomatosis
8
lymphangioendotheliomatosis thrombocytopenia
8
bevacizumab treatment
4
treatment multifocal
4
thrombocytopenia multifocal
4
thrombocytopenia mlt
4
mlt rare
4
rare disorder
4
disorder characterized
4
characterized proliferation
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!